Clinical trial Recruiting at 1 site Observational Ages 18 to 90 Women only

Characterizing circulating tumor cells in breast cancer patients

Official title: Ultrasensitive BIOsensing Platform for Multiplex CELLular Protein PHEnotyping at Single-cell Level

Run by Istituti Clinici Scientifici Maugeri SpA · NCT06048835 · Data updated 2026-11-12

This study is testing a new device to collect and analyze cancer cells from the blood of breast cancer patients to help tailor treatments for them.

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexWomen only
Enrollment80 (estimated)
SponsorIstituti Clinici Scientifici Maugeri SpA
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Pavia, Lombardy)
StatusRecruiting
StartedDecember 1, 2022
Main results expectedSeptember 30, 2025
Study endsDecember 31, 2028
Registry record updatedJune 23, 2026
Trial IDNCT06048835 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include female patients diagnosed with metastatic breast cancer or early-stage breast cancer who are candidates for surgery.

Probably not a fit

Patients with any other neoplastic disease will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a novel device for isolating and characterizing circulating tumor cells (CTCs) in breast cancer patients. It will involve consecutive patients diagnosed with various types of breast cancer, including metastatic and early-stage cases, as well as a control group of healthy volunteers. Blood samples will be collected at specific time points to analyze CTCs and gather clinical information, with the goal of improving patient stratification and personalized treatment approaches. The study is set to last for 24 months, starting from December 2022.

Why it matters

Potential benefit: If successful, this study could lead to improved methods for early detection of metastasis in breast cancer patients, enhancing personalized treatment strategies.

How similar studies have gone: While there have been various approaches to CTC detection, this study's specific methodology and device development represent a novel approach in the field.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* female patients with diagnosis of metastatic breast cancer, confirmed by clinical practice staging exams.
* female patients with biopsy-confirmed diagnosis of early-breast cancer candidate for primary surgery after multidisciplinary evaluation.
* patients not affected by any neoplastic disease.

Exclusion Criteria:

* Diagnosis of any neoplastic disease

Where it's running

  • Istituti Clinici Scientifici Maugeri SpA
    Pavia, Lombardy, Italy
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.